Orlistat EMA [Design Issues]

posted by Pharma_88 – India, 2020-11-27 14:51 (1240 d 07:06 ago) – Posting: # 22089
Views: 1,475

Dear All,

This is regarding Orlistat for EMA submission. We have US product specific guidance available but I am unable to find EMA guidance (most probably its not there).

My question is whether is it required to add third arm (The reference product at 2 x 60 mg or 120 mg tid) as per US OGD for EMA? whether regualotry will accept this design as per FDA or 2WCO is sufficient (The test & reference product at 60 mg tid as crossover)?

thanks.

Complete thread:

UA Flag
Activity
 Admin contact
22,988 posts in 4,825 threads, 1,655 registered users;
39 visitors (0 registered, 39 guests [including 5 identified bots]).
Forum time: 22:57 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5